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Background: Abuse of prescription drugs, particularly opioid analgesics, has become a major source of injury
mortality and morbidity in the United States. To prevent the diversion and misuse of controlled substances, many
states have implemented prescription drug monitoring programs (PDMPs). This study assessed the impact of state
PDMPs on drug overdose mortality.
Methods: We analyzed demographic and drug overdose mortality data for state-quarters with and without PDMPs
in 50 states and the District of Columbia during 1999–2008, and estimated adjusted risk ratios (aRRs) and 95%
confidence intervals (CIs) of drug overdose mortality associated with the implementation of state PDMPs through
multivariable negative bionomial regression modeling.
Results: During the study period, annual national death rates from drug overdose increased by 96%, from 5.7
deaths per 100,000 population in 1999 to 11.2 in 2008. The impact of PDMPs on drug overdose mortality varied
greatly across states, ranging from a 35% decrease in Michigan (aRR = 0.65; 95% CI = 0.54–0.77) to a more than
3-fold increase in Nevada (aRR = 3.37; 95% CI = 2.48–4.59). Overall, implementation of PDMPs was associated with an
11% increase in drug overdose mortality (aRR = 1.11; 95% CI = 1.02–1.21).
Conclusions: Implementation of PDMPs did not reduce drug overdose mortality in most states through 2008.
Program enhancement that facilitates the access and use of prescription drug monitoring data systems by
healthcare practitioners is needed.
Keywords: Policy intervention; Prescription drug; OverdoseBackground
Drug overdose has become a leading cause of injury
mortality and morbidity in the United States, resulting
in more than 34,000 deaths and 1.2 million emergency
department visits each year (Centers for Disease Control
and Prevention CDC 2012a; Substance Abuse and Mental
Health Services Administration SAMHSA 2010a). Of
the total mortality from drug overdose where a drug
was specified, almost three-quarters involved one or more
prescription drug (Centers for Disease Control and
Prevention CDC 2011). About three-quarters of the deaths
due to prescription drug overdose involved opioid analge-
sics (e.g., oxycodone, methadone and hydrocodone), and* Correspondence: GL2240@cumc.columbia.edu
1Department of Anesthesiology, Columbia University, 622 West 168th St,
PH5-505, New York, NY 10032, USA
2Department of Epidemiology, Columbia University, 722 West 168th St,
5th Floor, New York, NY 10032, USA
Full list of author information is available at the end of the article
© 2014 Li et al.; licensee Springer. This is an Op
Attribution License (http://creativecommons.or
in any medium, provided the original work is pabout one third of non-fatal emergency department visits
due to prescription drug overdose involved opioid analge-
sics, benzodiazepines (e.g., alprazolam, clonazepam, diaze-
pam, and lorazepam), and antidepressants (CDC 2011,
SAMHSA 2010a). Collectively, opioid analgesics, benzodi-
azepines and antidepressants accounted for the overwhelm-
ing majority of the increase in mortality and morbidity
from drug overdose in the United States in the past two de-
cades (Centers for Disease Control and Prevention 2010;
Hall et al. 2008; Paulozzi 2007).
A major contributing factor of the ongoing drug over-
dose epidemic is the overall increase in the availability of
controlled substances. From 1991 to 2010, the annual
number of prescriptions for opioid analgesics rose from
approximately 75 million to almost 210 million (National
Institute on Drug Abuse NIDA 2011; Volkow 2008; Volkow
and McLellan 2011). Retail outpatient pharmacy sales, which
in 2007 accounted for 80% of the total consumption ofen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Li et al. Injury Epidemiology 2014, 1:9 Page 2 of 8
http://www.injepijournal.com/content/1/1/9opioid analgesics and benzodiazepines, also showed
marked increases between 1998 and 2007 (Food and
Drug Administration FDA 2010). Increases in controlled
substance prescribing and retail sales were associated with
more use; per capita consumption of opioid analgesics
quadrupled from 74 milligrams in 1997 to 369 milligrams
in 2007 (Manchikanti and Singh 2008).
Per capita consumption of opioid analgesics and over-
dose mortality are positively correlated at the state level
(Paulozzi and Ryan 2006). Medical examiner data from
West Virginia indicate that of pharmaceutical overdose
fatalities, 63% were attributable to drug diversion and
21% to doctor-shopping (Hall et al. 2008). The 2009
National Survey on Drug Use and Health found that
65% of nonmedical users of prescription drugs obtained
these medications from friends or relatives, 20% from
physicians, 5% from drug dealers or strangers, 1% from
the internet, and 4% from other sources (e.g., stealing or
using a fake prescription) (Substance Abuse and Mental
Health Services Administration SAMHSA 2010b).
In response to the drug overdose epidemic, the federal
government has intensified prevention efforts in recent
years (Centers for Disease Control and Prevention CDC
2012a). One of the most important initiatives is the
Harold Rogers Prescription Drug Monitoring Program
(PDMP), through which the federal government has pro-
vided competitive funding since 2002 to an increasing
number of states for establishing statewide electronic
databases of dispensed prescriptions for controlled
substances. Another important initiative, enacted in 2005,
the National All Schedules Prescription Electronic
Reporting Act began appropriating funds to support
PDMP programs in fiscal years 2009 and 2010 (Finklea
et al. 2013). The PDMP is purported to enhance the
capacity of law enforcement agencies as well as public
health officials to identify and investigate unusual pre-
scribing, dispensing, and procuring patterns. Such
surveillance data may also help ensure the legitimate
use of controlled substances. As of April 19, 2012, 48
states and the District of Columbia have enacted
PDMP legislation, including 40 states with operational
PDMPs (Alliance of States with Prescription Drug
Monitoring Programs 2013).
Preliminary data about the impact of state PDMPs on
prescription drug consumption and overdose have been
inconsistent. While some studies indicate that PDMPs
were effective in reducing the consumption and abuse of
opioid analgesics at the population level (Reifler et al.
2012; Simeone and Holland 2006), others found no evi-
dence that implementing PDMPs had any appreciable
impact on the overall consumption of opioids and drug
overdose mortality (Paulozzi and Stier 2010; Paulozzi et al.
2011). Most of these studies were limited to data for the
early period of PDMPs and few took into considerationthe substantial statutory variations in state PDMPs. The
present study aims to expand previous research by
assessing the associations of PDMP status and PDMP
characteristics with drug overdose mortality at both the




This observational study used a “natural experiment”
design, with implementation of state PDMPs as the inter-
vention of interest. Whether and when a state implemented
the intervention during the study period were not deter-
mined by random assignment or by any systematic selec-
tion process. The associations of PDMP status and PDMP
characteristics with drug overdose mortality were evaluated
through the analysis of state-level time series data.
Data sources
Data on drug overdose deaths for the years 1999–2008
came from the multi-cause-of-death files of the National
Center for Health Statistics. Part of the National Vital
Statistics System, the multi-cause-of-death files are a
census of all deaths occurring within the United States,
based on death certificates compiled by individual
states. Data collected from the death certificate include
the decedent’s demographic characteristics, such as age,
sex and race, and up to 20 causes of death coded
according to the International Classification of Diseases,
10th Revision (ICD-10) (Miniño et al. 2011; National
Center for Health Statistics NCHS 2011). Drug over-
dose deaths were identified by screening the causes of
death based on ICD-10 codes X40–X44 (unintentional
poisoning due to drugs) and Y10–Y14 (poisoning due to
drugs of undetermined intent). Deaths of undetermined
intent were incorporated in the drug overdose death
counts because in some states a large portion of poison-
ing deaths were coded as undetermined intent (Warner
and Chen 2012, Warner et al. 2013).
Annual population data for each state and the District
of Columbia came from the bridged race intercensal and
postcensal population estimates, developed jointly by the
US Census Bureau and the National Center for Health
Statistics (National Center for Health Statistics NCHS
2009). Data on annual unemployment rates for each
state and the District of Columbia were obtained from
the US Bureau of Labor Statistics, based on the methods
used in the Current Population Survey (Bureau of Labor
Statistics BLS 2008).
Information about state PDMPs was obtained from
the US Drug Enforcement Administration (United States
Department of Justice US DOJ 2008) and the review of
PDMP characteristics conducted by the Kentucky All
Schedule Prescription Electronic Reporting Program
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plementation date of a state PDMP refers to the date
when electronic collection of prescription drug data
began. For each implemented PDMP, four characteristics
were examined: 1) type of governing agency (Department
of Health, Board of Pharmacy, or Other [mostly offices
related to public safety and drug control]); 2) statutory
requirement for committee oversight of the program’s
administration and evaluation (yes or no); 3) explicit
provision that imposes no expectation on practitioners
to access the statewide electronic database of dispensed
prescriptions before prescribing or dispensing (yes or no);
and 4) statutory authority to monitor non-controlled sub-
stances (yes or no) (Blumenschein et al. 2010).
Statistical analysis
The unit of analysis was the state-quarter, in which quar-
ters were delineated by the months January–March,
April–June, July–September, and October–December. A
state-quarter was coded as having a PDMP if the state
had an operational prescription drug monitoring pro-
gram any time during the quarter. During the 10-year
study period, there were a total of 2040 state-quarters
(10×4×51; the District of Columbia was treated as a
state), including 619 in which PDMPs were operational
in 31 states with varying implementation dates. The rela-
tionship between PDMP implementation and drug over-
dose mortality was assessed by contrasting data for
state-quarters with and without PDMPs.
The adjusted risk ratios (aRRs) of drug overdose mor-
tality associated with the implementation of PDMPs and
95% confidence intervals (CIs) were estimated through
the negative binomial generalized estimating equation
regression model. The negative binomial distribution
accounts for greater variation and approximates the
counts of drug overdose deaths within state-quarters
better than the Poisson distribution (Zeleterman 2002).
The generalized estimating equations were used to
account for the autoregressive correlation of drug over-
dose deaths across time within a state (Ballinger 2004).
State population counts in natural logarithms were
included in the multivariable regression models as an
offset term.
Possible confounding factors considered in the statis-
tical analysis included time trend (calendar year), demo-
graphic characteristics (percent of the population that
was male, percent of the population aged 35–54 years,
percent of the population that was white), geographic
region (Northeast, Midwest, South, and West), macro-
economic condition (unemployment rate), and accuracy
of reported drug overdose deaths (type of the death
investigation system, and other poisoning death rate).
In this study, state death investigation systems were
categorized into three groups based on the title of themedicolegal officials in the state: 1) coroners; 2) medical
examiners; and 3) combination of coroners and medical
examiners (Fierro 2003; Hanzlick 2007; Hanzlick and
Parrish 1996). Deaths due to poisoning of other substances
(“other poisoning deaths”) were identified from the multi-
cause-of-death data files based on ICD-10 codes X45–X49
(unintentional poisoning by alcohol, organic solvents,
pesticides, and other substances), X60–X69 (intentional
self-poisoning (suicide) by drugs), and X85–X90 (assault
by poisoning (homicide) by drugs).
Covariates significant at the p < 0.05 level were in-
cluded in the final model. Data were analyzed using
SAS 9.2 M2 (SAS Institute, Cary, NC) and Stata version
11.2 (StataCorp LP, College Station, TX).
Results
From 1999 to 2008, annual national death rates from
drug overdose per 100,000 population increased 96%,
from 5.7 to 11.2. During the 10-year study period, a total
of 254,507 deaths from drug overdose were recorded;
40.6% of them occurred in 619 state-quarters with
operational PDMPs. The overall death rate from drug
overdose in state-quarters with PDMPs was higher than
in state-quarters without PDMPs (9.51 vs. 8.26 per
100,000 per year, p < .0001). The excess mortality from
drug overdose was more pronounced in state-quarters
with PDMPs that were governed by pharmacy boards, that
had the statutory authority to monitor non-controlled
substances, or that imposed no expectation on practi-
tioners to access the statewide electronic database of
dispensed prescriptions (Table 1). When the death rates
from drug overdose were examined by year, there was
little difference between state-quarters with and without
PDMPs (Figure 1).
Multivariable modeling revealed that implementation
of PDMPs was associated with an 11% increase in drug
overdose mortality (aRR = 1.11; 95% CI: 1.02–1.21), with
the greatest increase observed in PDMPs that imposed
no expectation on practitioners (aRR = 1.17; 95% CI:
1.02–1.34; Table 1). Relative to the calendar year 1999,
drug overdose mortality risk increased progressively
throughout the study period. Other state-level factors
associated with significantly increased drug overdose
mortality were being in the west region, having a med-
ical examiner system, having an unemployment rate of
6% or higher, and having a higher poisoning mortality
rate from suicides and homicides involving drugs and
poisonings from substances other than drugs (Table 2).
Results from the multivariable models, including the
estimated effect of PDMPs on drug overdose mortality,
did not change to any meaningful degree when a one-
year lag was introduced to the implementation date or
when the implementation date was replaced with the
date when the state PDMP legislation was enacted.
Table 1 Number of states, number of state-quarters, number of drug overdose deaths, annualized death rate per
100,000 population, and adjusted risk ratio of drug overdose mortality by prescription drug monitoring program
implementation status and characteristics, United States, 1999–2008
PDMP Status/
Characteristic








Without PDMP (Ref) 20 1421 151051 8.26 (8.21–8.30) 1.00
With PDMP 31 619 103456 9.51 (9.45–9.57) 1.11 (1.02–1.21)
PDMP governing agency
Department of Health 7 163 34467 8.22 (8.13–8.30) 1.09 (0.92–1.27)
Board of Pharmacy 17 315 32198 12.10 (11.97–12.24) 1.14 (1.00–1.30)
Other 7 141 36791 9.14 (9.05–9.23) 1.05 (0.91–1.22)
Statutory requirements for committee oversight
Yes 12 152 30366 9.97 (9.86–10.08) 1.07 (0.95–1.22)
No 19 467 73090 9.33 (9.26–9.40) 1.13 (1.02–1.26)
Explicit laws that impose no expectation on practitioners
Yes 11 176 23403 10.50 (10.36–10.63) 1.17 (1.02–1.34)
No 20 443 80053 9.25 (9.19–9.32) 1.08 (0.96–1.20)
Statutory authority to monitor non-controlled substances
Yes 8 89 6840 11.35 (11.09–11.63) 1.01 (0.79–1.29)
No 23 530 96616 9.40 (9.34–9.46) 1.13 (1.02–1.24)
aAdjusted for year, geographic region, medical examiner type, unemployment rate and poisoning mortality rate from other substances. CI = Confidence Interval;
PDMP = Prescription Drug Monitoring Program.
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mortality was used as the outcome or when the analysis
was restricted to states with medical examiner systems.
The impact of PDMPs on drug overdose mortality
varied markedly across states (Table 3). Implementation of
PDMPs was associated with a significantly decreased risk
of drug overdose mortality in three states, no significantFigure 1 Annual death rate from drug overdose per 100,000 populat
Status and Year, United States, 1999–2008; PDMP = Prescription drugeffect in 11 states, and a significantly increased risk in
17 states (Table 3). The greatest reduction in drug over-
dose mortality associated with PDMP implementation
was in Michigan (aRR = 0.65; 95% CI: 0.54–0.77) and
the largest increase in drug overdose mortality associ-
ated with PDMP implementation was in Nevada (aRR =
3.37; 95% CI: 2.48–4.59).ion by prescription drug monitoring program implementation
monitoring program.
Table 2 Unadjusted and adjusted risk ratio and 95%
confidence interval of drug overdose mortality according
to prescription drug monitoring program implementation






No (Ref) 1.00 1.00
Yes 1.17 (1.07–1.27) 1.11 (1.02–1.21)
Year
1999 (Ref) 1.00 1.00
2000 1.08 (1.01–1.15) 1.08 (1.02–1.15)
2001 1.17 (1.04–1.32) 1.13 (1.02–1.24)
2002 1.38 (1.23–1.55) 1.25 (1.02–1.38)
2003 1.57 (1.38–1.79) 1.38 (1.24–1.55)
2004 1.70 (1.50–1.93) 1.54 (1.39–1.70)
2005 1.84 (1.62–2.08) 1.67 (1.50–1.86)
2006 1.99 (1.72–2.30) 1.87 (1.66–2.10)
2007 2.06 (1.81–2.34) 1.81 (1.60–2.04)
2008 2.20 (1.93–2.50) 1.71 (1.51–1.92)
Region
East (Ref) 1.00 1.00
Midwest 0.70 (0.55–0.89) 0.77 (0.59–1.01)
South 1.07 (0.89–1.27) 1.07 (0.89–1.29)
West 1.22 (0.99–1.51) 1.20 (0.98–1.46)
Death investigation
system typea
Coroner (Ref) 1.00 1.00
Coroner/Medical examiner 1.13 (0.75–1.71) 1.05 (0.77–1.42)
Medical examiner 1.38 (0.91–2.10) 1.28 (0.93–1.77)
Unemployment rate
<6% (Ref) 1.00 1.00
≥6% 1.05 (0.99–1.23) 1.07 (1.03–1.11)
Suicides and homicides involving
drugs and poisoning from
substances other than drugs
1.19 (1.13–1.26) 1.16 (1.10–1.23)
aStates with a coroner system were ID, IN, KS, LA, ND, NE, NV, SD, WY; States
with a combination of coroner and medical examiner systems were AK, AL, AR,
CA, CO, GA, HI, IL, KY, MN, MO, MS, MT, NY, OH, PA, SC, TX, WA, WI; and states
with a medical examiner system were AZ, CT, DC, DE, FL, IA, MA, MD, ME, MI,
NC, NH, NJ, NM, OK, OR, RI, TN, UT, VT, VA, WV (Hanzlick 2007; Hanzlick and
Parrish 1996; Standing Bear 2012). CI = confidence interval; PDMP= Prescription
Drug Monitoring Program; RR = risk ratio.
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Results of this study indicate that implementing PDMPs
did not reduce drug overdose mortality in most states
through 2008. This finding is consistent with previous
reports (Paulozzi et al. 2011; Brady et al. 2014). Pau-
lozzi et al. (2011) analyzed annual state-level mortality
and drug consumption data from 1999 to 2005 andfound no discernible impact of PDMPs on either drug
overdose mortality or per capita consumption of opioid
analgesics.
The lack of effectiveness of state PDMPs in reducing
drug overdose mortality could be attributed to several
factors. Foremost is the severely limited use of the elec-
tronic databases of dispensed prescriptions by physicians
and pharmacists due to difficult accessibility and insuf-
ficient incentives (Green et al. 2011). Use of state
PDMP databases by healthcare professionals is further
hampered by liability concerns. Of the 31 implemented
PDMPs included in this study, 11 contained provisions
exempting practitioners from the obligation to access the
state PDMP database, and these 11 PDMPs appeared to
be associated with greater drug overdose mortality than
other PDMPs. Other factors limiting the effectiveness of
PDMPs include barriers to interstate data sharing and
inadequate healthcare provider training on prescribing
controlled substances (Manchikanti 2007; McLellan and
Turner 2008; Volkow and McLellan 2011).
It is possible that the greater drug overdose mortality
associated with PDMPs was due to residual confounding
from factors that were controlled for and imperfectly
measured, and from unmeasured variables. For example,
controlling for census regions may not adequately con-
trol for geographic variations in overdose death between
states in different geographic regions. Specifically, the
cultural region of Appalachia has been greatly affected
by the overdose epidemic and spans 13 states and 3 census
regions. Thus, controlling for census region may not
adequately control for the drug overdose epidemic in
Appalachia. However, it is also plausible that the in-
creased risk of drug overdose mortality might reflect
unintended criminal justice consequences of the inter-
vention. PDMPs were designed and implemented pri-
marily for law enforcement purposes. During the study
period, state PDMP databases served mostly as a tool
for drug control agencies to identify and investigate
healthcare practitioners and patients engaging in fraudu-
lent activities. It is evident that law enforcement alone is
insufficient to control drug abuse and might in fact be
counterproductive because drug users could be forced to
riskier practices (Cooper et al. 2005) and are especially
susceptible to fatal overdose during the two weeks imme-
diately after release from prison (Binswanger et al. 2007;
Lim et al. 2012).
While state PDMPs share substantial uniformity in the
structure of centralized statewide data systems and basic
elements of electronically transmitted prescription data,
they differ in many key features, such as statutory require-
ments for committee oversight, and for data access and
reporting. This study examined four of these features—
type of governing agency, requirement for committee
oversight, explicit provision exempting practitioners from
Table 3 Adjusted risk ratio and 95% confidence interval of drug overdose mortality associated with the
implementation of the prescription drug monitoring program by State, United States, 1999–2008
State Adjusted risk ratioa (95% CI) State Adjusted risk ratioa (95% CI)
Michigan 0.65 (0.54–0.77) Ohio 1.15 (1.03–1.29)
Virginia 0.77 (0.66–0.89) Alabama 1.16 (1.02–1.33)
New York 0.86 (0.74–0.99) Louisiana 1.18 (0.84–1.65)
Maine 0.91 (0.80–1.04) Oklahoma 1.18 (1.03–1.36)
Mississippi 0.95 (0.84–1.09) Hawaii 1.28 (1.07–1.52)
North Carolina 0.95 (0.86–1.06) Idaho 1.35 (1.03–1.77)
California 0.96 (0.85–1.09) New Mexico 1.35 (1.18–1.56)
Massachusetts 0.96 (0.82–1.12) Kentucky 1.42 (1.24–1.64)
Texas 1.00 (0.87–1.16) Indiana 1.44 (1.20–1.73)
Arizona 1.02 (0.94–1.10) Utah 1.47 (1.16–1.87)
South Carolina 1.04 (0.93–1.16) Pennsylvania 1.49 (1.33–1.68)
Tennessee 1.05 (0.94–1.17) West Virginia 1.49 (1.28–1.73)
Illinois 1.11 (0.98–1.25) Wyoming 1.53 (1.23–1.89)
Rhode Island 1.11 (0.91–1.35) North Dakota 1.72 (1.43–2.07)
Colorado 1.12 (1.00–1.25) Nevada 3.37 (2.48–4.59)
Connecticut 1.12 (1.00–1.25)
aAdjusted for year, geographic region, medical examiner type, unemployment rate and poisoning mortality rate from other substances; and estimated separately
for each state using state-quarter data for the individual state and those without an operational Prescription Drug Monitoring Program throughout the study
period (AK, AR, DC, DE, FL, GA, IA, KS, MD, MN, MT, MO, NE, NH, NJ, OR, SD, VT, WA, and WI).
CI = confidence interval.
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statutory authority to monitor non-controlled sub-
stances—and found that none of them had a significant
protective effect on drug overdose mortality. Some of
these features, such as an explicit provision exempting
healthcare practitioners from the obligation to use the
state PDMP database, appear to be detrimental. A re-
cent study that examined the comparative effectiveness
of “proactive” PDMPs (i.e., those providing unsolicited
reports to healthcare practitioners and law enforce-
ment agencies) and other PDMPs did not find any sig-
nificant difference in drug overdose mortality between
the two groups (Paulozzi et al. 2011). These findings
suggest that inadequate utilization of the PDMP data-
base by healthcare practitioners may largely void the
potential health benefit of the program, rendering pro-
gram characteristics essentially irrelevant.
Although variations in state PDMPs have been well
documented (Blumenschein et al. 2010), there is limited
information about the effectiveness of PDMPs for indi-
vidual states (Office of National Drug Control Policy
ONDCP 2011; Prescription Drug Monitoring Program
Center of Excellence at Brandeis 2013). There are now
best practice recommendations that have been devel-
oped to help states analyze PDMP data (Clark et al.
2012). The state-level analysis in this study indicates that
PDMPs implemented in Michigan, Virginia, and New
York are most effective and those implemented in Nevada,North Dakota, Wyoming, West Virginia, and Pennsylvania
are least effective. These findings may facilitate further
research through case studies and other qualitative
methods to delineate program elements and implemen-
tation processes responsible for the divergent effective-
ness of the state PDMPs.
The above findings should be interpreted with caution
for several reasons. First, results from this observational
study are susceptible to information bias and unmeasured
confounding. Although the multi-cause-of-death data files
represent a census of all deaths occurring within the
United States, the accuracy in the recorded drug overdose
deaths and including those involving opioids may vary
from state to state (Warner and Chen 2012; Warner et al.
2013). Opioid analgesic rates are subject to differential
classification of opioids (Warner et al. 2013). There is
conflicting evidence regarding the accuracy of the coding
and determination of drug overdose deaths (Landen et al.
2003, Manini et al. 2011). This study confirms that
reported drug overdose mortality is significantly higher in
states where injury deaths are investigated by medical
examiners than in states where such deaths are investi-
gated by coroners. Whereas adjusting for the type of the
death investigation system is necessary, it is likely insuffi-
cient to control for information bias in the drug overdose
mortality data. Second, this study is limited to data for the
years 1999–2008 and the findings should not be extrapo-
lated beyond 2008 given the extensive changes in state
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supplemental funding through the National All Schedules
Prescription Electronic Reporting Act to bolster their
PDMPs, such as the accessibility of prescription data and
the capacity for interstate information exchange (Alliance
of States with Prescription Drug Monitoring Programs
2013). Third, drug overdose mortality in this study is
based on ICD-10 codes X40–X44 and Y10–Y14, which
include overdose deaths involving prescription drugs as
well as overdose deaths involving other substances. While
prescription drugs are not always identified in death cer-
tificate data and 60% of overdose deaths are thought to be
related to prescription drugs, drug overdose mortality in
this study may include deaths caused by methampheta-
mine, cocaine, heroin, and other illicit drugs, which are
beyond the purview of PDMPs. There is preliminary evi-
dence that as prescription drugs become more difficult to
procure, illicit drugs such as heroin may be substituted.
Because the outcome definition in this analysis does not
distinguish between illicit and prescription drugs, if there
were fewer deaths resulting from prescription drugs with
the implementation of PDMP programs, this effect would
not be detected in this analysis. Fourth, this study con-
trolled for ICD-10 codes X60–X64 (suicide by “drug”
overdose) and X86 (homicide by “drug” overdose), as
well as overdose/poisoning of other substances (e.g.,
X65–X69), which may or may not involve drugs. Suicide
by drug overdose and homicide by drug overdose are
likely more relevant to PDMPs than poisoning from
other substances. Finally, this study assessed the pos-
sible impact of implementing PDMPs on drug overdose
mortality only. It is noteworthy that the primary purpose
of PDMPs is to prevent diversion of controlled substances,
not drug overdose per se. Although the majority of drug
overdose deaths involve the use of diverted drugs (Hall
et al. 2008), targeting drug diversion alone through law
enforcement may not be sufficient to reduce drug over-
dose mortality. To control the ongoing drug overdose
epidemic, a multifaceted approach is needed. Recent re-
ports and commentaries have called for using prescrip-
tion data and insurance restrictions to help prevent
procurement of controlled substance prescriptions from
multiple healthcare providers, augmenting healthcare
provider training on pain management, implementing
evidence-based guidelines for the management of pain,
and improving access to drug treatment and expanding
community-based harm reduction programs (Centers
for Disease Control and Prevention 2012b; United Nations
Office on Drugs and Crime UN ODC 2013; Volkow and
McLellan 2011).
Conclusions
Despite its limitations, this study adds compelling evi-
dence that up to 2008, implementing PDMPs had notreduced drug overdose mortality in most states. The lack
of effectiveness is likely due to the severely limited
utilization of state PDMP data systems by healthcare
practitioners. Enhancing the capacity and accessibility
of state PDMPs is imperative to facilitate integrating the
prescription drug monitoring data system into clinical
practice. Continuing efforts to refine and strengthen
prevention programs are necessary to effectively reduce
drug overdose mortality and morbidity.
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